[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Correspondence
November 01, 2005

Concern About the Pediatric Eye Disease Investigator Group 2-Year Follow-up Study

Arch Ophthalmol. 2005;123(11):1615-1616. doi:10.1001/archopht.123.11.1615-b

In 2002, the Pediatric Eye Disease Investigator Group (PEDIG) compared penalization with atropine sulfate vs patching for treating moderate amblyopia.1 That initial article did not include data on stereoacuity and fusion in these 2 groups because many of the patients receiving atropine sulfate were still pharmacologically dilated at the outcome examination. Readers were promised “definitive long-term safety data on the completion of the 2-year follow-up.”1 Although I eagerly awaited that publication, I was unsatisfied and somewhat distressed when I read it.2 I believe the study did not provide the long-term safety data that I had anticipated.

First Page Preview View Large
First page PDF preview
First page PDF preview
×